Drug Search Results
More Filters [+]

Netupitant

Alternative Names: netupitant, Akynzeo
Latest Update: 2024-04-26
Latest Update Note: Clinical Trial Update

Product Description

Netupitant is a highly selective neurokinin-1 receptor antagonist and palonosetron is a serotonin 5-HT3 receptor antagonist with a distinct pharmacological profile.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26613606/)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Chile | Croatia | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Germany | Hong Kong | Hungary | India | Indonesia | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Tunisia | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Netupitant

Countries in Clinic: Brazil, United Kingdom, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Nose Cancer

Phase 2: Breast Cancer|Central Nervous System Cancer|Cervical Cancer|Gallbladder Cancer|Lymphoma|Motion Sickness|Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SWC999

P2

Recruiting

Pregnancy Outcomes|Central Nervous System Cancer|Motion Sickness

2023-12-31

NCT04362449

P2

Recruiting

Gallbladder Cancer

2023-02-02

NCI-2017-00599

P3

Completed

Nose Cancer

2022-02-14

OLNEPA

P2

Completed

Breast Cancer|Nose Cancer

2021-12-17

Recent News Events